Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Pneumologie ; 74(12): 864-870, 2020 Dec.
Article in German | MEDLINE | ID: mdl-32663890

ABSTRACT

BACKGROUND: Implant of indwelling pleural catheters (IPC) represents an established therapy method in addition to pleurodesis for symptomatic recurrent benign and malignant pleural effusions (BPE and MPE).There are only few studies on IPC safety during follow-up, especially with regard to infection and pneumothorax rates.The aim of our investigation was to determine the complication frequency after IPC implant and its predictive factors in patients with BPE vs. MPE. METHODS: Retrospective analysis of all IPC implantations in the pneumology department at the University Hospital Dresden during 2015 - 2018. RESULTS: An IPC was implanted in 86 patients (43 m/f each; age 66.9 ±â€Š13.3 years) with symptomatic BPE and MPE. BPE and MPE was present in 12.8 % (11/86) and 87.2 % (75/86) of the patients, respectively.A predominantly small and asymptomatic pneumothorax was detectable as an immediate complication in 43/86 (50 %) of patients; 34/43 (79 %) of patients did not require any specific therapy. For 9/43 patients, IPC suction was required for a median period of three days; 8/43 patients had a large pneumothorax with partial or complete regression after a median period of two days.Catheter infection developed in 15.1 % (13/86) of the total group and 36.4 % (4/11) of the BPE vs. 12 % (9/75) of the MPE after a median period of 87 (BPE/MPE 116/87) days. This was more common in BPE (p = 0.035), large pneumothorax (4/8 patients; p = 0.015) and longer catheter dwell times (124 ±â€Š112 vs. 71 ±â€Š112 days; p = 0.07). CONCLUSION: Small pneumothoraxes are frequent after IPC implantation, but usually do not require specific therapy. IPC infection was detected in 15.1 % of all patients after a median period of 87 days. This was more common in patients with BPE, longer catheter dwell times and large pneumothorax.


Subject(s)
Catheters, Indwelling/adverse effects , Drainage/instrumentation , Pleural Effusion, Malignant/therapy , Pleural Effusion/surgery , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pleural Effusion, Malignant/pathology , Pleurodesis , Retrospective Studies , Treatment Outcome
2.
Pneumologie ; 74(6): 374-386, 2020 Jun.
Article in German | MEDLINE | ID: mdl-32557509

ABSTRACT

RSV induces an acute viral disease with involvement of the respiratory tract. It can be notably life-threatening for infants but also for older adults. New RSV-subtypes are constantly evolving globally. The knowledge about epidemiology, hygiene measures, diagnostics and clinical feature is essential not only for the paediatrician. Vaccines or specific therapeutics are still missing. This article gives an overview with focus on RSV in adults. In addition, molecular pathological characteristics of the virus are explained, research approaches concerning vaccines and therapeutics are mentioned and current problems in management are discussed.


Subject(s)
Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Human , Humans , Respiratory Insufficiency
3.
Pneumologie ; 72(3): 207-221, 2018 Mar.
Article in German | MEDLINE | ID: mdl-29514356

ABSTRACT

Influenza is an acute viral disease with involvement of the respiratory tract. It can be life-threatening. New types of influenza viruses can spread globally and cause influenza pandemics with exalted case numbers. The knowledge about epidemiology, preventive hygiene and vaccination, diagnostic, therapy and clinics are essential for the general practitioner as well as the specialist. This article gives an overview with focus on seasonal influenza in adults. In addition, molecular pathological characteristics of influenza viruses are explained and current problems in influenza management are named. The course consists of 10 multiple-choice questions to consolidate the acquired knowledge.


Subject(s)
Influenza, Human , Pandemics/prevention & control , Vaccination , Adult , Humans , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Neuraminidase
4.
Clin Microbiol Infect ; 24(3): 306.e1-306.e6, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28710027

ABSTRACT

OBJECTIVES: Community-acquired pneumonia (CAP) is associated with a high risk of respiratory failure or septic organ dysfunction. Lactate is an established early marker of prognosis and sepsis severity, but few data exist in patients with CAP. METHODS: We performed a retrospective cohort study of consecutive adult CAP patients without treatment restrictions or direct intensive care unit admission. Lactate was measured as a point-of-care test within the capillary admission blood gas analysis, and its prognostic value was compared to the CRB/CURB-65 criteria by multivariate and receiver operating characteristic (ROC) curve analysis. The primary endpoint was the combination of need for mechanical ventilation, vasopressors, intensive care unit admission or hospital mortality. RESULTS: Of 303 included patients, 75 (25%) met the primary endpoint. After ROC analysis, lactate predicted the primary endpoint (area under the curve 0.67) with an optimal cutoff of >1.8 mmol/L. Of the 76 patients with lactate above this threshold, 35 (46%) met the primary endpoint. After multivariate analysis, the predictive value of lactate was independent of the CRB/CURB-65 scores. The addition of lactate >1.8 mmol/L to the CRB/CURB-65 scores resulted in significantly improved area under the curves (0.69 to 0.74, p 0.005 and 0.71 to 0.75, p 0.008 respectively). Fourteen (42%) of 33 and 11 (39%) of 28 patients meeting the endpoint despite presenting with 0 or 1 CRB/CURB-65 criteria had lactate >1.8 mmol/L. CONCLUSIONS: Admission lactate levels significantly improved the prognostic value of the CRB/CURB-65 scores in CAP patients. Lactate may therefore be considered a rapid, cheap and broadly available additional criterion for the assessment of risk in patients with CAP.


Subject(s)
Community-Acquired Infections/diagnosis , Community-Acquired Infections/pathology , Diagnostic Tests, Routine , Lactic Acid/blood , Pneumonia/diagnosis , Pneumonia/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , ROC Curve , Respiration, Artificial/statistics & numerical data , Retrospective Studies , Severity of Illness Index , Survival Analysis , Young Adult
5.
Pneumologie ; 70(9): 605-7, 2016 Sep.
Article in German | MEDLINE | ID: mdl-27603949

ABSTRACT

UNLABELLED: A patient presented himself with pungent, breath-dependent right chest pain and dyspnea at rest in our emergency department. The physical examination and the ECG revealed no relevant findings. The laboratory results showed an increased CRP, leukocytosis, elevated D-dimers and a respiratory partial insufficiency. In the thoracic CT angiography unclear pulmonary nodules (PN) were seen. The bronchoscopy was macroscopically normal. In the BAL yeasts and a high proportion of immune senescence cells (CD57+) were identified. After a pulmonary wedge resection resulted histologically an epithelioid cell-granulomatous inflammation. Molecular pathological a mycelium genome, in particular Pichia guilliermondii (PC) was detected. The therapy with fluconazole was successful. PC rarely causes candidemia, increased in immunocompromised patients. In our judgement this is in Europe the first described case of PC-infection in a patient, which presented no predisposition to infection with opportunistic pathogens apart from type 2 diabetes. CONCLUSION: It should be thought of fungal infection by these pathogens group in case of unclear PN, especially in combination with possibly predisposing factors.


Subject(s)
Fungemia/diagnosis , Fungemia/microbiology , Lung Diseases, Fungal/diagnosis , Lung Diseases, Fungal/microbiology , Multiple Pulmonary Nodules/diagnosis , Multiple Pulmonary Nodules/microbiology , Pichia/classification , Pichia/isolation & purification , Diagnosis, Differential , Humans , Male , Middle Aged , Rare Diseases
7.
Natl Med J India ; 26(4): 214-5, 2013.
Article in English | MEDLINE | ID: mdl-24758444

ABSTRACT

BACKGROUND: Disseminated histoplasmosis is a chronic granulomatous disease caused by the dimorphic fungus, Histoplasma capsulatum. Clinical presentation can vary from the acute pulmonary to the chronic disseminated form. In India, disseminated histoplasmosis often presents with pyrexia of unknown origin with a presentation similar to 'disseminated tuberculosis' involving the adrenal glands and bone marrow. Due to rarity of the disease, data are lacking regarding its clinical presentation and outcome among immunocompromised and immunocompetent patients. METHODS: During January 2000 to December 2010, we identified 37 patients of disseminated histoplasmosis and attempted to characterize the differences between immuno- compromised and immunocompetent patients. Demographic characteristics, clinical presentation, risk factors, laboratory findings, diagnostic yield, treatment received and prognosis were noted and compared between the two groups. RESULTS: Eleven of 37 patients with disseminated histo- plasmosis were immunocompromised and 26 were immuno- competent. Comparison of their clinical features showed a higher frequency of skin lesions in the immunocompromised compared to the immunocompetent group (54.5% v. 11.5%). Pancytopenia and anaemia were more common among the immunocompromised (81.8%) compared to the immunocompetent (46.2%) group. In the immuno- compromised patients, the diagnosis was made most often by bone marrow aspirate and culture (72.7%) compared to the immunocompromised group where the diagnosis was most often obtained by adrenal gland biopsy and fungal cultures (57.7%). The cure rate was significantly higher in the immunocompetent group (73% v. 45%). CONCLUSION: The clinical presentation and outcome of patients with disseminated histoplasmosis differs among immunocompromised and immunocompetent patients.


Subject(s)
Adrenal Glands/pathology , Bone Marrow/pathology , Histoplasmosis/complications , Histoplasmosis/diagnosis , Immunocompetence , Immunocompromised Host , Adult , Anemia/immunology , Anemia/microbiology , Antifungal Agents/therapeutic use , Biopsy , Female , Histoplasmosis/drug therapy , Humans , Male , Middle Aged , Pancytopenia/immunology , Pancytopenia/microbiology , Skin Diseases/immunology , Skin Diseases/microbiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...